Plain-English summaries of peptide research, protocol design, and compound mechanisms. Written for clinicians, researchers, and practitioners exploring the science of optimization.
The synergy between BPC-157 and Thymosin Beta-4 isn't just clinical folklore — it's rooted in distinct but complementary repair pathways. Here's what the research actually shows about combining them.
KLOW combines GHK-Cu, BPC-157, TB-500, and KPV — each targeting different nodes of the tissue repair and inflammatory modulation axis. We walk through the rationale and the citations behind each pairing.
Much of the Epithalon enthusiasm traces back to Russian longevity research from the 1980s–2000s. We examine the original studies, methodological caveats, and how modern replication efforts compare.
Both are Russian-developed nootropics derived from ACTH and tuftsin. Their mechanisms diverge sharply — one acts on BDNF and dopaminergic pathways, the other on GABA and serotonin. When to use which, and why.
Tirzepatide is a dual agonist; Retatrutide adds glucagon receptor activity. That third receptor fundamentally changes the metabolic profile — and the research implications for hepatic and energy expenditure pathways.
Oral NAD+ precursors have well-known bioavailability limits. IV and subcutaneous routes change the pharmacokinetic curve dramatically — but not always in the direction researchers expect. A look at the comparative data.